Europeiska unionen - svenska - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcell - antineoplastiska medel - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Europeiska unionen - svenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiska medel - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetylfumarat - multipel skleros, skovvis förlöpande - immunsuppressiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Europeiska unionen - svenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiska medel - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

amarox pharma gmbh - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans; propylenglykol hjälpämne; natriumlaurilsulfat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - fingolimodhydroklorid - kapsel, hård - 0,5 mg - natriumlaurilsulfat hjälpämne; fingolimodhydroklorid 0,56 mg aktiv substans; propylenglykol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medical valley invest ab - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

unimedic pharma ab - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

avansor pharma oy - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans